SAVA - Cassava Sciences, Inc.

Cassava Sciences, Inc.

6801 N. Capital of Texas Hwy, Bldg 1
Suite 300
Austin, TX 78731
United States
512 501 2444
https://www.cassavasciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 26

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Remi Barbier	Founder, Chairman, Pres & CEO	1.11M	297.42k	1960
Mr. Eric J. Schoen	Chief Financial Officer	426.61k	N/A	1968
Mr. R. Christopher Cook	Sr. VP, Company Sec. & Gen. Counsel	457.64k	N/A	1964
Dr. James W. Kupiec M.D.	Chief Medical Officer	400k	N/A	1953
Dr. George Thornton	Sr. VP of Technology	N/A	N/A	N/A
Mr. Michael Zamloot	Sr. VP of Technical Operations	N/A	N/A	N/A
Dr. Michael Marsman Pharm.D.	Sr. VP of Regulatory Affairs	N/A	N/A	N/A
Dr. Lindsay H. Burns Ph.D.	Sr. VP of Neuroscience	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Corporate governance

Cassava Sciences, Inc.’s ISS governance QualityScore as of 1 May 2023 is 9. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.